Key result
Cardiac contractility modulation yields a ~19-point LVEF improvement in phospholamban-related cardiomyopathy.
Why the study?
Does cardiac contractility modulation improve left ventricular ejection fraction and symptoms in a patient with phospholamban p.Arg14del related cardiomyopathy intolerant to standard medical therapy?
Case Report (n=1)
No
Does cardiac contractility modulation improve left ventricular ejection fraction and symptoms in a patient with phospholamban p.Arg14del related cardiomyopathy intolerant to standard medical therapy?
Cardiac contractility modulation may serve as an effective bailout therapy to improve LVEF and functional capacity in patients with PLN-related cardiomyopathy who remain symptomatic and are intolerant to optimal medical therapy.
Answers are grounded in this paper and cite their sources.
May support CCM as bailout in medication-intolerant PLN cardiomyopathy; leaves open efficacy in prospective trials.
Background: Cardiac contractility modulation (CCM) is a novel device-based therapeutic option in patients with heart failure with reduced ejection fraction who are not eligible for cardiac resynchronization therapy. Cardiac contractility modulation enhances cardiac contractility by delivering high-voltage non-excitatory electrical impulses during the absolute refractory period. Cardiac contractility modulation is known to improve left ventricular ejection fraction (LVEF), quality of life, and exercise capacity in heart failure (HF) patients. Case summary: variant [p.(Arg14del), Dutch founder mutation]. Due to progressive deterioration of LVEF (25%) despite maximally tolerated guideline-directed medical therapy (GDMT), a CCM device was implanted. After implantation, the patient experienced a sharp thoracic and interscapular pain after stimulation of one of the two leads. This lead was turned-off and the output on the other lead was increased to maximal output of 7,5 V. After 3 months, there were less signs and symptoms of HF. New York Heart Association class improved from class III to II and the patient was free of thoracic pain. Echocardiography demonstrated further improvement of LVEF to 44% and a decrease in end-diastolic pressures. Discussion: , persistent symptoms despite maximally tolerated GDMT. Although it was necessary to deactivate one of the both leads due to thoracic pain, LVEF and HF symptoms significantly improved. Further research is needed to elaborate on the potential role of CCM therapy in genetic cardiomyopathies.
No takes yet. Share an insight, caveat, or question.
Verelst et al. (2024) conducted a case report in Phospholamban p.Arg14del related cardiomyopathy (n=1). Cardiac contractility modulation was evaluated on Left ventricular ejection fraction and New York Heart Association (NYHA) class. Cardiac contractility modulation therapy improved left ventricular ejection fraction from 25% to 44% and functional class from III to II in a patient with phospholamban p.Arg14del related cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: